Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OTO-313 in Subjective Tinnitus
NCT03918109Phase 2Completed
- Sponsor
- Otonomy, Inc.
- Start
- Apr 2019
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in tinnitus comparing OTO-313 with Placebo (2 arms). Primary endpoints: Audiometry - Pure Tone Average at Day 57 and Otoscopic Examination - Presence of Perforation at Day 57. Started Apr 2019; status: completed.
02
Drugs
gacyclidine
03
Conditions
tinnitus
Beyond the preview
Go deeper on NCT03918109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03918109.